Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Capecitabine dominant over fluorouracil/levofolinate in Japan

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan. PharmacoEconomics 27: 597-608, No. 7, 2009

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Capecitabine dominant over fluorouracil/levofolinate in Japan. Pharmacoecon. Outcomes News 586, 6 (2009). https://doi.org/10.2165/00151234-200905860-00014

    Download citation

    Keywords

    • Colon Cancer
    • Capecitabine
    • Probabilistic Sensitivity Analysis
    • Healthcare Payer
    • Oral Capecitabine